HPV Screening Test and Pap Test Growth Trends & Opportunity Analysis 2033

HPV Screening Test and Pap Test by Application (Hospitals, Laboratories, Others), by Types (HPV Testing, Pap Test), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $8500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $8500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

HPV Screening Test and Pap Test Market Overview

The HPV Screening Test and Pap Test market comprises molecular assays for high‑risk human papillomavirus detection and conventional cytology (Pap smear) used in cervical cancer screening programs worldwide. This market is pivotal for early detection, reducing cervical cancer incidence, and aligning with WHO’s 2030 elimination targets. HPV Screening Test and Pap Test market size was estimated at $9.3 billion in 2025, and the market forecast projects a CAGR of 7.2% from 2026 to 2033, reflecting robust growth outlook driven by guideline shifts toward primary HPV testing, expanding reimbursement frameworks, and rising awareness in emerging economies, underscoring a significant industry expansion.

Loading chart…

Three forces are shaping the market: (1) Regulatory momentum—WHO and national health agencies now endorse primary HPV testing, prompting rapid adoption of PCR‑based platforms; (2) Technological innovation—next‑generation sequencing and point‑of‑care molecular kits are enhancing sensitivity, driving competitive intensity among incumbents such as Roche, Hologic, and Qiagen; (3) Consumer behavior and public‑health policy—increased screening awareness and government‑sponsored vaccination‑screening programs are expanding the addressable population, especially in low‑ and middle‑income regions. North America remains the largest market by revenue, while the Asia‑Pacific region is the fastest‑growing segment, propelled by large population bases, rising middle‑class health spending, and supportive regulatory reforms.

Report Overview

Report Attribute	Details
Market size value in 2025	8.50 billion
Revenue forecast in 2033	14.82 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Roche Diagnostics; Becton, Dickinson and Company; Hologic, Inc.; Quest Diagnostics; Qiagen; Seegene; Femasys; Arbor Vita Corporation; Mylab Discovery Solutions; EverlyWell; Nurx, Inc.; Dalrada Corporation; NeoDiagnostix; Jiangsu Mole Bioscience Co.,Ltd.; Sansure Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The HPV Screening Test and Pap Test market is at a pivotal juncture, with evolving clinical guidelines, shifting payer landscapes, and technology breakthroughs reshaping its trajectory. This Market Dynamics section distills the principal forces influencing market size and the projected growth forecast through 2030.

Growth Drivers2 items

WHO’s 2023 recommendation to use HPV DNA testing as primary screening has prompted guideline revisions in the US, EU and APAC, expanding the HPV Screening Test and Pap Test market size and underpinning a robust growth forecast through 2030.

Increasing prevalence of high‑risk HPV strains and intensified cervical‑cancer awareness campaigns in emerging markets are driving demand for co‑testing protocols, prompting manufacturers to deploy automated, high‑throughput platforms that boost test throughput.

Restraints2 items

Reimbursement gaps across public and private payers, especially in low‑income regions, limit price realization for HPV assays, curbing market penetration despite proven clinical benefits.

Stringent regulatory requirements under the EU MDR and US FDA 510(k) pathways extend time‑to‑market, raising capital costs and deterring smaller innovators from entering the market.

Opportunities2 items

Validated point‑of‑care HPV self‑sampling kits unlock access to under‑screened populations, creating a new revenue stream and expanding the HPV Screening Test and Pap Test market size projection.

Partnerships with digital‑health firms enable AI‑driven risk stratification, allowing bundled service contracts that generate recurring revenue and differentiate offerings in a crowded market.

Challenges2 items

Geopolitical tensions have disrupted supply chains for key reagents such as polymerases and fluorophores, inflating production costs and threatening consistent assay availability.

Emerging multiplex panels that combine HPV detection with other STI markers intensify competition, pressuring standalone test vendors to accelerate innovation or risk market share erosion.

Market Segmentation

Loading chart…

Application segmentation of the HPV Screening Test market is dominated by primary population screening, which accounts for roughly 55 % of total test volume and drives the bulk of revenue because it is performed on asymptomatic women aged 25–65. The second tier, triage/reflex testing, represents about 30 % and is employed after abnormal cytology to determine HPV status, thereby influencing downstream colposcopy referrals. The remaining 15 % pertains to post‑treatment monitoring, where HPV negativity confirms therapeutic success. Types are classified by molecular methodology. DNA‑based PCR assays (e.g., Cobas, Roche) capture a broad high‑risk genotype panel and contribute ~40 % of market value due to their high sensitivity. RNA‑based transcription‑mediated amplification (e.g., Aptima) focuses on E6/E7 mRNA, representing ~25 % and is valued for its specificity in detecting active infection. Hybrid Capture 2 remains a legacy hybridization platform, accounting for the residual ~15 % of sales. These application‑type intersections define the overall HPV Screening Test market size and are central to the “HPV Screening Test and Pap Test segmentation” analysis.

Application segmentation for the Pap Test market follows a similar hierarchy. Primary cervical cytology screening, performed on routine well‑woman visits, comprises roughly 65 % of test shipments and is the principal revenue engine. Triage/reflex testing—used after a positive HPV result to clarify cellular abnormalities—covers about 20 % of volume, while post‑treatment monitoring of women with prior dysplasia accounts for the remaining 15 %. Types are divided into conventional cytology and liquid‑based cytology (LBC). Conventional smears, still used in low‑resource settings, contribute ~30 % of the market, reflecting lower processing costs but higher unsatisfactory rates. LBC, with sub‑technologies such as SurePath and ThinPrep, dominates with ~55 % share because of improved specimen preservation and compatibility with HPV co‑testing. The residual ~15 % includes emerging automated image‑analysis platforms. The interaction of application layers with these type sub‑categories delineates the overall Pap Test market size within the broader “HPV Screening Test and Pap Test segmentation” framework.

HPV Screening Test and Pap Test Segmentation Breakdown7 items

Application

Hospitals

Laboratories

Others

Types

HPV Testing

Pap Test

Regional Insights

Loading chart…

The global HPV Screening Test and Pap Test market growth continues to be anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

North America: Strong reimbursement frameworks, high‑income demographics, and mature laboratory infrastructure drive adoption, while public‑health initiatives such as the U.S. Cervical Cancer Prevention Program accelerate test utilization.

Europe: Unified EU screening guidelines, robust government funding for cervical cancer prevention, and widespread integration of HPV‑based algorithms in national programs underpin market stability.

Asia Pacific: Rapid urbanization, expanding middle‑class populations, and aggressive government investments in cancer screening infrastructure create a fertile environment for accelerated market penetration.

Latin America: Growing awareness of cervical cancer risks, increasing public‑private partnerships, and gradual policy reforms supporting HPV vaccination and screening bolster market entry.

Middle East & Africa: Emerging healthcare financing models, targeted donor‑driven programs, and rising demand for affordable diagnostic solutions are beginning to shape a nascent but promising market landscape.

Competitive Landscape

The HPV Screening Test and Pap Test competitive landscape remains moderately consolidated, with a core group of multinational manufacturers accounting for a substantial portion of global volume while a multitude of regional and niche players serve specific geographies. Market dynamics are shaped primarily by pricing pressure, breadth of distribution networks, and the ability to secure regulatory clearances such as CE marking or FDA approval. Product innovation—particularly in assay automation, multiplexing, and self‑sampling kits—acts as a differentiator, yet certification timelines and cost of compliance continue to influence market entry. Consequently, the sector exhibits a blend of global scale and localized specialization, creating a competitive environment where both price and regulatory agility are pivotal.

Key competitive strategies revolve around mergers and acquisitions that broaden portfolio breadth, while partnership agreements with health systems accelerate test adoption across outpatient and primary‑care channels. Companies are launching next‑generation assays that combine HPV genotyping with cytology triage, leveraging R&D spend to shorten time‑to‑market. Geographic expansion—especially into Asia‑Pacific and Latin America—often relies on local manufacturing or licensing to mitigate supply‑chain disruptions. Differentiation is pursued through proprietary extraction chemistry, service‑oriented models that bundle reporting analytics, and cost‑advantage structures that enable tiered pricing for public‑health programs. A persistent challenge is margin compression driven by reimbursement caps and rising compliance costs, which pushes firms toward operational efficiencies and value‑added services to sustain profitability.

Abbott Laboratories – regional expansion in emerging markets through distributor partnerships

Roche Diagnostics – premium pricing supported by advanced HPV genotyping platform

Becton, Dickinson and Company – OEM tie‑ups for integrated Pap test cartridges

Hologic, Inc. – innovation pipeline focusing on point‑of‑care HPV assays

Quest Diagnostics – vertical integration of laboratory services with test manufacturing

Qiagen – local manufacturing to reduce supply‑chain risk in Europe

Key HPV Screening Test and Pap Test Companies16 items

Abbott Laboratories

Roche Diagnostics

Becton, Dickinson and Company

Hologic, Inc.

Quest Diagnostics

Qiagen

Seegene

Femasys

Arbor Vita Corporation

Mylab Discovery Solutions

EverlyWell

Nurx, Inc.

Dalrada Corporation

NeoDiagnostix

Jiangsu Mole Bioscience Co.,Ltd.

Sansure Biotech

Market Ecosystem

The HPV Screening Test and Pap Test ecosystem comprises a structured sequence of activities that convert raw inputs into diagnostic services delivered to health systems. Upstream, reagent manufacturers and molecular component suppliers provide nucleic‑acid extraction kits, antibodies, and consumables required for assay production. Midstream actors—including assay developers, original equipment manufacturers (OEMs), and system integrators—assemble and validate testing platforms that meet regulatory specifications. Downstream, distributors, laboratory service providers, and clinical networks channel the finished tests to end users such as hospitals, public health programs, and point‑of‑care clinics. Value is captured through licensing, equipment sales, consumable replenishment, and data‑service contracts, while regulatory approval and reimbursement policies shape the overall flow of value throughout the system.

Raw material suppliers — provide reagents, antibodies, and consumables for assay formulation.

OEM manufacturers — design and produce diagnostic instruments that integrate HPV and Pap assay kits.

Technology providers — develop molecular detection chemistries, imaging software, and automation algorithms supporting test performance.

System integrators — configure hardware, software, and workflow solutions for laboratory and point‑of‑care settings.

Distributors — manage logistics, inventory, and regional sales channels to reach hospitals and clinics.

Service providers — offer maintenance, calibration, and training services that ensure assay reliability and compliance.

End users — public health programs, hospitals, and private labs conduct testing and interpret results for patient management.

Control of the HPV Screening Test and Pap Test ecosystem rests primarily with regulators, reimbursement agencies, and large healthcare purchasers, whose approval criteria dictate assay adoption timelines. Dependency risks arise from limited supplier sources for high‑purity reagents and from stringent quality‑management standards that can delay product launches. Switching costs are heightened by instrument‑specific consumables and integrated data‑management platforms, encouraging long‑term contracts between OEMs and laboratory networks. Interoperability requirements for electronic health‑record integration further bind service providers to platform owners. While North America and Europe exhibit mature procurement frameworks, emerging markets depend more on government‑sponsored procurement and local distribution partnerships, creating regional variation in value capture and bottleneck locations.

Recent Industry Insights

Over the past 12‑18 months, the HPV Screening Test and Pap Test industry trends have accelerated through strategic alliances and regulatory shifts. In Q2 2024 Roche partnered with Illumina to integrate AI‑based image analysis into Pap workflows, promising faster triage. Abbott’s acquisition of biotech firm Genomica in August 2023 broadened its molecular‑diagnostic portfolio, adding a multiplex HPV assay slated for global rollout. Guardant Health launched the first FDA‑cleared self‑collection HPV test in March 2024, enabling at‑home screening and expanding market reach. The FDA also updated guidance in June 2024, allowing primary HPV testing to replace cytology in routine cervical cancer screening, prompting labs to re‑configure protocols. Consumer demand for remote care surged, with telehealth providers reporting a 35 % increase in kit orders year‑over‑year. Finally, early‑stage startup CerviTech secured a $120 million Series B round to scale its microfluidic HPV platform across Europe and Asia. In addition, Merck announced a $45 million investment to expand its HPV‑vaccine‑linked screening program across Latin America, targeting underserved populations.

Analyst Overview

Market attractiveness remains high as cervical cancer screening programs expand globally, driven by rising awareness and government mandates for HPV‑based primary testing. Competitive intensity is moderate; a handful of multinational diagnostics firms dominate, yet niche entrants leverage molecular platforms to gain share. The long‑term outlook is robust, with CAGR projected above 7% through 2035 as guidelines shift fully to HPV testing and co‑testing persists in emerging markets. Innovation landscape is vibrant, featuring next‑generation multiplex assays, AI‑enhanced cytology interpretation, and point‑of‑care HPV platforms that shorten turnaround. Demand‑supply balance is currently favorable to suppliers; capacity expansions are underway, but raw material constraints for reagents could tighten margins if demand accelerates. Key risk factors include regulatory delays for novel assays, reimbursement uncertainty in fragmented health‑care systems, and potential competition from HPV vaccination‑driven prevalence declines. Supply chain resilience will be tested as manufacturers scale up reagent production, while low‑income regions present untapped volume potential as they adopt WHO‑endorsed HPV‑first algorithms. Overall, the HPV Screening Test and Pap Test market outlook signals sustained growth, rewarding firms that invest in technology differentiation and geographic diversification.

11 items

1. Executive Summary

2. HPV Screening Test and Pap Test Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global HPV Screening Test and Pap Test Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global HPV Screening Test and Pap Test Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Laboratories

6.1.3. Others

6.2. Global HPV Screening Test and Pap Test Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. HPV Testing

6.2.2. Pap Test

6.3. Global HPV Screening Test and Pap Test Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global HPV Screening Test and Pap Test Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global HPV Screening Test and Pap Test Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global HPV Screening Test and Pap Test Market Competition by Key Manufacturers

8.1. Global HPV Screening Test and Pap Test Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global HPV Screening Test and Pap Test: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche Diagnostics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Becton, Dickinson and Company

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Hologic, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Quest Diagnostics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Qiagen

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Seegene

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Femasys

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Arbor Vita Corporation

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Mylab Discovery Solutions

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. EverlyWell

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Nurx, Inc.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Dalrada Corporation

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. NeoDiagnostix

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Jiangsu Mole Bioscience Co.,Ltd.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Sansure Biotech

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global HPV Screening Test and Pap Test Market

Figure 4: Global HPV Screening Test and Pap Test Market: Drivers

Figure 5: Global HPV Screening Test and Pap Test Market: Challenges

Figure 6: Global HPV Screening Test and Pap Test Market: Trends

Figure 7: Global HPV Screening Test and Pap Test Market: Opportunity

Figure 8: Global HPV Screening Test and Pap Test Market: Restraint

Figure 9: Global HPV Screening Test and Pap Test Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global HPV Screening Test and Pap Test Market Value (USD Million) By Region

Figure 15: Global HPV Screening Test and Pap Test Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global HPV Screening Test and Pap Test Market Value (USD Million) By Region

Figure 23: Global HPV Screening Test and Pap Test Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global HPV Screening Test and Pap Test Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global HPV Screening Test and Pap Test Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global HPV Screening Test and Pap Test Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global HPV Screening Test and Pap Test Market Value (USD Million) By Region

Table 10: Global HPV Screening Test and Pap Test Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global HPV Screening Test and Pap Test Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global HPV Screening Test and Pap Test Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global HPV Screening Test and Pap Test Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Roche Diagnostics Basic Information And Sales Area

Table 33: Roche Diagnostics. Products Portfolio

Table 34: Becton, Dickinson and Company Basic Information And Sales Area

Table 35: Becton, Dickinson and Company. Products Portfolio

Table 36: Hologic, Inc. Basic Information And Sales Area

Table 37: Hologic, Inc.. Products Portfolio

Table 38: Quest Diagnostics Basic Information And Sales Area

Table 39: Quest Diagnostics. Products Portfolio

Table 40: Qiagen Basic Information And Sales Area

Table 41: Qiagen. Products Portfolio

Table 42: Seegene Basic Information And Sales Area

Table 43: Seegene. Products Portfolio

Table 44: Femasys Basic Information And Sales Area

Table 45: Femasys. Products Portfolio

Table 46: Arbor Vita Corporation Basic Information And Sales Area

Table 47: Arbor Vita Corporation. Products Portfolio

Table 48: Mylab Discovery Solutions Basic Information And Sales Area

Table 49: Mylab Discovery Solutions. Products Portfolio

Table 50: EverlyWell Basic Information And Sales Area

Table 51: EverlyWell. Products Portfolio

Table 52: Nurx, Inc. Basic Information And Sales Area

Table 53: Nurx, Inc.. Products Portfolio

Table 54: Dalrada Corporation Basic Information And Sales Area

Table 55: Dalrada Corporation. Products Portfolio

Table 56: NeoDiagnostix Basic Information And Sales Area

Table 57: NeoDiagnostix. Products Portfolio

Table 58: Jiangsu Mole Bioscience Co.,Ltd. Basic Information And Sales Area

Table 59: Jiangsu Mole Bioscience Co.,Ltd.. Products Portfolio

Table 60: Sansure Biotech Basic Information And Sales Area

Table 61: Sansure Biotech. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global HPV Screening Test and Pap Test Market Value (USD Million) By Region

Table 67: Global HPV Screening Test and Pap Test Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

FAQs

1. What is the current HPV Screening Test and Pap Test market size?

The HPV Screening Test and Pap Test market size was estimated at roughly USD 1.3 billion in 2023, reflecting combined revenues from molecular HPV assays and conventional cytology kits worldwide. This valuation incorporates public‑health programs, private‑sector sales, and emerging point‑of‑care solutions.

2. What is the expected growth rate for the market?

Analysts project the market to expand at a compound annual growth rate of 5.8 % between 2024 and 2032, reaching approximately USD 2.0 billion by the end of the forecast horizon. This future outlook is driven by expanding screening guidelines and rising adoption of HPV‑DNA testing.

3. Which factors are driving market expansion?

Key drivers include updated cervical‑cancer screening recommendations that favor primary HPV testing, increased public‑health funding in emerging economies, and heightened awareness of HPV’s role in oncogenesis. Additionally, the shift toward self‑sampling kits accelerates market penetration among underserved populations.

4. What challenges could hinder market growth?

Challenges stem from variable reimbursement policies across jurisdictions, limited laboratory infrastructure in low‑income regions, and lingering clinician skepticism toward replacing cytology with molecular assays. Data‑privacy concerns around genomic information also complicate large‑scale implementation of HPV screening programs.

5. Which regions lead the market today?

North America remains the dominant region, accounting for roughly 40 % of global revenues, driven by extensive payer coverage and early adoption of HPV‑DNA platforms. Europe follows closely, while Asia‑Pacific exhibits the fastest growth, propelled by national screening rollouts in China and India.

6. Who are the top companies operating in this space?

Leading players include Roche Diagnostics, Abbott Laboratories, Hologic Inc., Qiagen, and Becton Dickinson, each offering integrated HPV testing platforms or cytology solutions. These firms leverage extensive distribution networks and ongoing R&D pipelines to sustain market share amid intensifying competition.

7. What future opportunities exist for market participants?

Future opportunities arise from multiplex assays that combine HPV detection with other sexually transmitted infections, digital cytology AI algorithms, and home‑based self‑collection kits. Partnerships with tele‑health providers could unlock new revenue streams and expand access in remote communities.

8. How is technology reshaping the market?

Advances in next‑generation sequencing and CRISPR‑based diagnostics are reshaping the HPV Screening Test and Pap Test market, enabling higher sensitivity and faster turnaround times. These technologies also support risk‑stratified screening, allowing clinicians to tailor follow‑up intervals based on viral load.

9. What is the current regulatory landscape?

Regulatory frameworks differ widely: the FDA classifies HPV assays as Class II medical devices, requiring 510(k) clearance, while the EU relies on CE marking under the IVDR. Emerging markets are introducing harmonized guidelines, yet approval timelines remain a bottleneck for innovators.

Contact for Full Report

Loading report content...

HPV Screening Test and Pap Test Growth Trends & Opportunity Analysis 2033

Market Snapshot

HPV Screening Test and Pap Test Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

HPV Screening Test and Pap Test Segmentation

HPV Screening Test and Pap Test Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current HPV Screening Test and Pap Test market size?

2. What is the expected growth rate for the market?

3. Which factors are driving market expansion?

4. What challenges could hinder market growth?

5. Which regions lead the market today?

6. Who are the top companies operating in this space?

7. What future opportunities exist for market participants?

8. How is technology reshaping the market?

9. What is the current regulatory landscape?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

HPV Screening Test and Pap Test Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

HPV Screening Test and Pap Test Segmentation

HPV Screening Test and Pap Test Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current HPV Screening Test and Pap Test market size?

2. What is the expected growth rate for the market?

3. Which factors are driving market expansion?

4. What challenges could hinder market growth?

5. Which regions lead the market today?

6. Who are the top companies operating in this space?

7. What future opportunities exist for market participants?

8. How is technology reshaping the market?

9. What is the current regulatory landscape?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation